Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT ID: NCT00412750

Last Updated: 2011-07-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 159 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2009-02-28

Brief Summary

To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.

Conditions

Hepatitis B

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LdT+ PEG-INF

Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.

Group Type: EXPERIMENTAL

Telbivudine (LdT)

Intervention Type: DRUG

600 mg orally once daily for 104 weeks.

peginterferon alpha-2a

Intervention Type: DRUG

180 μg subcutaneous injection once a week for 52 weeks.

LdT Monotherapy

Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.

Group Type: EXPERIMENTAL

Telbivudine (LdT)

Intervention Type: DRUG

600 mg orally once daily for 104 weeks.

PEG-INF Monotherapy

Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.

Group Type: ACTIVE_COMPARATOR

peginterferon alpha-2a

Intervention Type: DRUG

180 μg subcutaneous injection once a week for 52 weeks.

Interventions

Telbivudine (LdT)

600 mg orally once daily for 104 weeks.

Intervention Type: DRUG

peginterferon alpha-2a

180 μg subcutaneous injection once a week for 52 weeks.

Intervention Type: DRUG

Other Intervention Names

Sebivo; Pegasys

Eligibility Criteria

Inclusion Criteria

Documented Chronic hepatitis B (CHB) defined by all of the following:

• Clinical history compatible with CHB
• Detectable serum Hepatitis B Surface Antigen (HBsAg) at the Screening visit and at least 6 months prior
• HBeAg-positive at the Screening visit
• Hepatitis B 'e' Antibody (HBeAb)-negative at the Screening visit
• History of evidence of chronic liver inflammation,
• Elevated serum Alanine aminotransferase (ALT) level (1.3 - 10 x upper limit of normal (ULN)) at the Screening visit
• Serum HBV DNA level ≥ 6 log10 copies/mL,
• Chronic liver inflammation on previous liver biopsy within the previous 24 months.

Exclusion Criteria

• Co-infection with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), or Human Immunodeficiency Virus (HIV).
• Has any of the following drug therapy:

• Previously been treated in a trial with telbivudine
• Received nucleoside or nucleotide therapy whether approved or investigational
• Received any immunomodulatory treatment in the 12 months before Screening for this study.
• Has a medical condition that required prolonged or frequent use of systemic acyclovir or famciclovir.
• Has a medical condition that requires frequent or prolonged use of systemic corticosteroids although inhaled or intra-articular corticosteroids are allowed.
• Has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs.
• Is currently abusing alcohol or illicit drugs or has a history of alcohol abuse illicit substance abuse within the preceding two years.
• Uses other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
• Is currently receiving methadone.
• Patient has any of the following:

• History of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.
• History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with previous findings suggestive of possible HCC should have the disease ruled out prior to entrance into the study.
• One or more additional known primary or secondary causes of liver disease other than hepatitis B, including steatohepatitis.
• History of clinical and laboratory evidence of chronic pancreatitis, or demonstrates a clinical and laboratory course consistent with current pancreatitis.
• Has laboratory values during screening visit not within normal limits.
• Is pregnant or breastfeeding.
• Is a women of child-bearing potential that is unwilling to practice birth control.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: lead

Responsible Party

novatis

Locations

Novartis

San Francisco, California, United States

Countries

United States

References

Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, Gane E, Lim SG, Fainboim H, Foster GR, Safadi R, Rizzetto M, Manns M, Bao W, Trylesinski A, Naoumov N. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol. 2015 Jan;62(1):41-7. doi: 10.1016/j.jhep.2014.08.021. Epub 2014 Aug 23.

Reference Type: DERIVED

PMID: 25152207 (View on PubMed)

Other Identifiers

CLDT600A2406

Identifier Type: -

Identifier Source: org_study_id

NCT00376389

Identifier Type: -

Identifier Source: nct_alias